Figure S10



Supplementary information, Figure S10 EGFR inhibition resensitizes *SMARCE1* deficient cells to MET and ALK kinase inhibitors in NSCLCs.

(A) Combination of EGFR and MET inhibitors synergistically inhibits growth of *SMARCE1* knockdown NSCLC cells driven by *MET* amplification. H1993 cells expressing pRS or sh*SMARCE1* vectors were cultured in the absence or presence of 300 nM Crizotinib, 150 nM EMD1214063, or 150 nM PHA665752. Cells were then fixed and stained with crystal violet after 14 days (untreated) or 34 days (treated). Crystal violet was then extracted with 10% Acetic Acid and measured at OD 590 nM. Error bars denote SD; * and ** denote p values <0.05 and <0.01 of three independent biological replicates respectively; ns, not significant.

(B) Combination of EGFR and ALK inhibitors synergistically inhibits growth of *SMARCE1* knockdown NSCLC cells harboring *EML4-ALK* translocation. H3122 cells expressing pRS or sh*SMARCE1* vectors were cultured in the absence or presence of 300 nM Crizotinib, 20 nM Ceritinib, 5 nM NVP-TAE684, 250 nM gefitinib or their combination as indicated. Cells were then fixed and stained with crystal violet after 10 days (untreated) or 28 days (treated). Crystal violet was then extracted with 10% Acetic Acid and measured at OD 590 nM. Error bars denote SD; * and ** denote p values <0.05 and <0.01 of three independent biological replicates respectively; ns, not significant.